Lilly Wins Appeal Upholding Patent for Alimta Cancer Drug

Eli Lilly & Co. (LLY) won a U.S. appeals court ruling that upholds the validity of a patent for the lung- cancer drug Alimta and blocks generic competition through 2017.

The U.S. Court of Appeals for the Federal Circuit today rejected arguments by Teva Pharmaceutical Industries Ltd. (TEVA) that the patent was invalid. It affirmed a lower court ruling. The decision was posted on the court’s website.

Alimta, whose chemical name is pemetrexed, generated $2.5 billion in sales last year for Indianapolis-based Lilly, making it the company’s third biggest-selling drug. Alimta is designed to hamper cancer cells’ ability to use folic acid to grow after an initial treatment with other drugs.

Teva, based in Petah Tikva, Israel, had argued that Lilly had patented a compound that wasn’t much different from what was covered by two earlier patents. The three-judge panel said the lower court was correct to rule that the 2017 patent is distinct from the earlier inventions.

“By affirming the district court ruling, we believe that the court fairly applied long-standing patent law principles,” Lilly General Counsel Robert Armitage said in a statement. “Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs.”

Denise Bradley, a spokeswoman for Teva, said the company had no comment.

The case is Eli Lilly & Co. v. Teva Parental Medicines Inc., 2011-1561, U.S. Court of Appeals for the Federal Circuit (Washington). The lower court case is Eli Lilly & Co. v. Teva Parenteral Medicines Inc., 08CV335, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: William McQuillen in Washington at bmcquillen@bloomberg.net Susan Decker in Washington at sdecker1@bloomberg.net

To contact the editor responsible for this story: Bernard Kohn at bkohn2@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.